Form 4: Neuronetics Director Robert Cascella Receives Significant Restricted Stock Unit Award

Neuronetics, Inc. Director Robert Cascella was granted 36,250 restricted stock units, increasing his beneficial ownership to 578,236 shares.

Summary

• Robert Cascella, a Director of Neuronetics, Inc. (STIM), acquired 36,250 shares of common stock on May 22, 2025.
• This acquisition was in the form of a Restricted Stock Unit (RSU) award.
• Each RSU represents a contingent right to receive one share of the Issuer's common stock.
• The RSUs are set to vest on the earlier of May 22, 2026, or the Reporting Person's Board-approved separation of service from the Issuer, subject to continuous service.
• Following this transaction, Mr. Cascella beneficially owns a total of 578,236 shares of Neuronetics common stock.

Sentiment

Score: 7

Explanation: The grant of restricted stock units to a director aligns management's interests with shareholders, indicating continued commitment, which is generally viewed positively.

Positives

• The grant of restricted stock units to a director aligns management's interests with those of the shareholders, as the value of the award is tied to the company's stock performance.
• The increase in beneficial ownership by a director demonstrates continued commitment and confidence in the company's future.

Future Outlook

The document indicates a future vesting event for the restricted stock units on May 22, 2026, or earlier upon Board-approved separation of service, contingent on continuous service.

Industry Context

This Form 4 filing is a standard disclosure of an insider transaction, specifically a compensation grant to a director. It does not provide broader industry context or trends.

Related Party Transactions

• The transaction involves the grant of restricted stock units to Robert Cascella, a Director of Neuronetics, Inc., which is a related party transaction as part of director compensation.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's financial interests with those of the shareholders, as the value of the award is tied to the company's stock performance, potentially encouraging decisions that enhance shareholder value.

Next Steps

• The 36,250 restricted stock units are expected to vest on the earlier of May 22, 2026, or the Reporting Person's Board-approved separation of service from the Issuer, subject to continuous service.

Key Dates

Keywords

Neuronetics, STIM, Robert Cascella, Form 4, SEC filing, insider transaction, restricted stock unit, RSU, director compensation, beneficial ownership